|1.||Struck, Anna-Winona: 1 article (07/2015)|
|2.||Nunns, Laura: 1 article (07/2015)|
|3.||Wu, Ming-Cheng: 1 article (07/2015)|
|4.||Law, Brian J C: 1 article (07/2015)|
|5.||Styles, Matthew Q: 1 article (07/2015)|
|6.||Micklefield, Jason: 1 article (07/2015)|
|7.||Butler, Mark S: 1 article (11/2014)|
|8.||Cheng, Mu: 1 article (11/2014)|
|9.||Huang, Johnny X: 1 article (11/2014)|
|10.||Cooper, Matthew A: 1 article (11/2014)|
07/01/2015 - "The mannosyl substituents of ramoplanin enhance aqueous solubility, which was important in the development of ramoplanin as a potential treatment for Clostridium difficile infections. "
01/01/1988 - "These results suggest that the clinical evaluation of ramoplanin as a topical antibacterial agent for the control of superficial infections caused by Staphylococcus spp. and for the eradication of methicillin-resistant S. "
06/01/2003 - "A randomized, double-blinded, placebo-controlled multicentre study is currently being conducted to determine whether ramoplanin will prevent VRE bloodstream infection in oncology patients who are neutropenic due to treatment for a haematological malignancy or a bone marrow/stem cell transplant."
01/01/1988 - "The antimicrobial activity of ramoplanin is limited to Gram-positive bacteria and its reportedly unacceptable administration side-effects suggest that any potential clinical role will be limited to the topical therapy of superficial skin infections and the eradication of bacteria, representing a possible nosocomial cross-infection source, from carriage sites. "
11/01/2014 - "Ramoplanin is an actinomycetes-derived antibiotic with broad-spectrum activity against Gram-positive bacteria that has been evaluated in clinical trials for the treatment of gastrointestinal vancomycin-resistant enterococci (VRE) and Clostridium difficile infections. "
05/01/2005 - "The completion of clinical trials will determine whether ramoplanin has a promising role as a treatment option for diarrhea due to C. "
05/01/2005 - "Clinical trials are investigating ramoplanin's oral administration for treatment of Clostridium difficile-associated diarrhea. "
06/01/2004 - "Ramoplanin is a glycolipodepsipeptide antibiotic with activity against gram-positive bacteria that is in clinical trials for prevention of vancomycin-resistant Enterococcus (VRE) bloodstream infections and treatment of Clostridium difficile diarrhea. "
01/01/2007 - "Ramoplanin, a macrocyclic depsipeptide, is unstable in the bloodstream but can be taken orally to treat Clostridium difficile colitis."
08/01/2006 - "This review compares the antibacterial activity and clinical activity of three glycopeptides, oritavancin, telavancin and dalbavancin, and the natural lipoglycopeptide, ramoplanin, which, being unstable in the bloodstream, is administered orally to treat Clostridium difficile colitis and for digestive tract decontamination. "
|4.||Gram-Positive Bacterial Infections
|5.||Wounds and Injuries (Trauma)
|4.||Anti-Bacterial Agents (Antibiotics)